ArticleBreast cancer (Tokyo, Japan)2025
Regional disparities in breast cancer healthcare in Japan: REAL-BC study.
Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors associated with central venous port implantation during breast cancer perioperative chemotherapy: a Japanese database study.Breast cancer (Tokyo, Japan) · 2026Article
- Geographic access to radiotherapy facilities in Japan.Journal of radiation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince 2007, the Basic Plans for Promoting Cancer Control (BPPCCs) have sought to enhance cancer care at designated cancer care hospitals (DCCHs) and implement population (PBCR)- and hospital (HBCR)-based cancer registries, among other activities. However, the impact of the BPPCCs on breast cancer care in Japan remains uncertain. This study sought to reveal the reality of regional disparities in the proportion of breast cancer patients' initial visits to DCCHs and the functionality of breast cancer in DCCHs.
methodsWe obtained data from the PBCR and HBCR in Japan, as well as administrative healthcare claims data (JMDC claims data), and data published by clinical societies in Japan for the period 2018 to 2021. We conducted descriptive analyses to determine the proportions of patients who received initial treatment for breast cancer at a DCCH. We also examined the quality of care in terms of staffing and functions.
resultsIn 2020, out of 79,062 breast cancer patients registered in the HBCR, 57.7% started initial treatment at a DCCH (range across 47 prefectures: 15.5%-89.8%) in Japan. The proportion of patients who visited a DCCH for initial treatment increased from 53.8% (2018) to 57.7% (2020). The median proportion of DCCHs certified by the Japanese Breast Cancer Society (JBCS) among the 47 prefectures was 62.50% (range: 16.7%-100.0%). The median number of patients per JBCS-certified specialist was 77.40 (range: 37.6-142.0). The proportions of DCCHs with claims for breast cancer-related service fees were 15.2% (range: 0.0%-50.0%) for cancer genome profiling tests, 62.0% (range: 0.0%-100.0%) for cancer BRCA1/2 genetic tests, and 92.8% (range: 60.0%-100.0%) for patient support system enhancement.
conclusionWe found regional disparities in the initial treatment and medical services for breast cancer care in Japan. The findings uncover opportunities to enhance the treatment of breast cancer in Japan. We anticipate that our data will be utilized as a valuable resource and as a key input for informing policy development tailored to the specific characteristics of the region and for designing programs to address the different needs of each prefecture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.